Oral solid dosage (OSD) forms, including tablets, capsules, granules and powders, represent a dominant mode of delivery for medications across a wide range of therapeutic areas, from cardiovascular diseases to various cancers. The global OSD contract manufacturing market is projected to grow considerably year-over-year to at least 2030. Meeting this growing demand requires more than simply scaling up existing processes. It necessitates a deep understanding of the evolving trends and challenges shaping the OSD landscape and a commitment to innovation.
In this white paper from Pfizer CentreOne, learn more about the OSD landscape and how drug manufacturers can proactively adapt their strategies to meet the evolving needs of patients worldwide.